The US Food and Drug Administration (FDA) is in discussions with OpenAI about using AI in drug evaluation.

The talks, held in recent weeks, involve a project called “cderGPT,” potentially linked to the FDA’s Center for Drug Evaluation and Research.

Jeremy Walsh, the FDA’s first AI officer, is reportedly leading the discussions, along with representatives from OpenAI and the Department of Health and Human Services.